Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Exclusion Criteria

• •1. Is nursing or pregnant
• •2. Has BMI \> 34.9 kg/m2.
• •3. Has a positive test for human immunodeficiency virus (HIV-1 or -2) hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg).
• •4. Receiving chronic systemic corticosteroid therapy \> 20 mg of prednisone daily.
• •5. Being treated with other anti-cancer therapies (approved or investigational).
• •6. Has, at the initiation of study drug, received cytotoxic chemotherapy or a Bruton's tyrosine kinase (BTK)-inhibitor (e.g. ibrutinib) within the past 3 weeks or rituximab within the past 2 months
• •7. Has an active infection requiring systemic antibiotics.
• •8. Has had surgery requiring general anesthesia within 4 weeks of starting the study.
• •9. Has autoimmune cytopenia (anemia, thrombocytopenia, leukopenia).
• •10. Has heart failure of Class III or IV.
• •11. Has sensory or motor neuropathy limiting daily activities.